Company intelligence / Profile preview

Mendus

Ownership: Private
Development stage: Phase 2

Overview

Mendus has demonstrated promising Phase II clinical data with its lead asset vididencel, particularly showing potential to reduce tumor recurrence and improve long-term survival in cancer patients. The company received positive feedback from both the FDA and EMA regarding registration trial preparations for vididencel in AML. Preparations are underway for pivotal-stage studies.

Therapeutic areas: Oncology
Modalities: Dendritic cell-based immunotherapies
Industry: Biotech

Drug pipeline

4 assets

ilixadencel

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Mendus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mendus.

Explore the full profile